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Health Effects of Oxygenated Fuels
by Maria G. Costantini
The use of oxygenated fuels is anticipated to increase over the next decades. This paper reviews the
toxicological andexposure information formethyltertiary-butyl ether(MTBE),afuel additive,andmethanol,
a replacement fuel, and discusses the possible health consequences ofexposure ofthe general public to these
compounds. For MTBE, the health effects information available is derived almost exclusively from rodent
studies, andtheexposure dataarelimitedtoafewmeasurementsatsomeservicestations.Basedonthesedata,
it appears unlikely that the normal population is at high risk of exposure to MTBE vapor. However, in the
absence of health and pharmacokinetic data in humans or in nonhuman primates, this conclusion is not
strongly supported. Similarly, there are a number of uncertainties to take into consideration in estimating
human risk from the use ofmethanol as a fuel. Although methanol maybe toxic to humans at concentrations
thatoverwhelm certain enzymes involved in methanol metabolism, thedataavailable provide littleevidenceto
indicate that exposure to methanol vapors from the use of methanol as a motor vehicle fuel will result in
adverse health effects. The uncertainties in this conclusion are based on the lack of information on dose-
response relationship at reasonable, projected exposure levels and ofstudies examining end points ofconcern
in sensitive species. In developing a quantitative riskassessment, more needstobe known about health effects
in primates or humans and the range ofexposure expected for the general public for both compounds.
Introduction
Oxygenated fuels include replacement fuels such as
methanol and ethanol and fuel additives such as methyl
and ethyl tertiary-butyl ethers (MTBE and ETBE) and
tertiary-amyl methyl ether (TAME). The interest in these
and other alternative fuels in the last decade stems not
only out of a concern for the country's dependence on
petroleum but also out of a desire to improve air quality. It
is anticipated thatfuelswith ahigher oxygen content than
conventional gasoline and diesel fuel will produce less CO
and hydrocarbons and may lead to lower ozone levels in
some regions. However, the introduction of oxygenated
fuels would increase exposure of the general public to
methanol or ethanol or the oxygenated additives and also
to their combustion byproducts. Exposure would be by
inhalation of unburned fuel in the exhaust or fuel vapors
either during refueling or normal heating ofthe fuel tank
or the engine. The issue ofhealth effects will include both
combustion andevaporative emissions ofcomplexmixtures
that will further undergo atmospheric transformation.
However, because such studieshave notbeenreported, itis
only possible to discuss components of the mixtures,
namely, MTBE and methanol. This paper presents an
overview ofthe information on exposure, metabolic trans-
formation, and health effects of the two oxygenated fuel
components, MTBE and methanol, which are now being
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used and are projected to be used more widely in the
United States in the future and whose effects following
inhalation exposure have been better characterized.
MTBE
MTBEwasoriginallyintroducedintheUnitedStatesin
the late 1970s as an octane enhancer at the time of lead
phase-out. Its use has increased recently in areas of the
country with severe air pollution problems. Currently,
approximately 20% of the gasoline sold in the United
States contains MTBE atlevels rangingfrom 2 to 15% (R.
Wilson, personal communication). Ambient concentrations
of MTBE at service stations are expected to be below 1
ppmbased on someactualmeasurements rangingfrom0.1
to 1 ppm (1).
The research conducted on the health effects ofMTBE
has been sponsored primarily by the MTBE Health
Effects Evaluation Task Force on behalfofseveral manu-
facturers who have agreed to perform certain health
effects studies in accordance with Section 4 of the Toxic
Substances Control Act. Some oftheinformation available
is derived from acute human clinical studies ofparenteral
exposure to MTBE as a potential therapeutic agent to
dissolve gallstones.
Metabolism and Pharmacokinetics
MTBE is a colorless liquid with limited water solubility
(4g/100 gwater). Inrats,thefirststepinthemetabolismof
MTBE is demethylation, with formation oftertiary-butyl
alcohol (TBA). This compound is further oxidized to
various products including 2-methyl-1,2-propanediol,M. G. COSTANTINI
Q-hydroxyisobutyric acid (2,3), acetone and formaldehyde
(4), and formic acid (5). Interestingly, TBA is not thought
to be a substrate of alcohol dehydrogenase like methanol
and other alcohols. The transformation ofTBAto formal-
dehyde appears to proceed in vitro via a mechanism
involving the interaction of TBA with hydroxyl radicals
generated from hydrogen peroxide produced by micro-
somes (4).
The disposition of MTBE in rats has been examined
after inhalation, oral, intravenous, and intraperitoneal
exposure using radioactive MTBE (Table 1). After expo-
sure by inhalation to 400 ppm for 6 hr (average total dose
285 mg/kg*), MTBE blood levels (a parameter often
used to characterize bodyburden) reached apeakvalue at
theend oftheexposure,whereas TBApeaked30minafter
exposure (7). At a higher exposure concentration (8000
ppm for 6 hr or 5700 mg/kg), the peak MTBE concentra-
tion was higher than expected from that at 400 ppm (35
times instead of 20 times greater), suggesting a possible
saturation ofthe enzyme catalyzing the demethylation of
MTBE. At the lower concentration, 400 ppm, the major
route ofMTBE elimination appeared tobeviathe kidneys
into the urine (65% of the radioactivity recovered) with
some MTBE eliminated via the lungs (17-22%) (2). At the
higher exposure, 8000 ppm, however, a larger fraction of
the recovered radioactivity was eliminated by the lungs
(54-59%) than through the urine (17-22%) (2).
Afteroral andintravenous administration ofMTBE ata
doseof40mg/kg,thepeakbloodMTBE concentrationwas
*Forthepurpose ofcomparison tootherroutesofexposure, theMTBE
dose after inhalation exposure can be calculated as the product of the
MTBE concentration in mg/m', the ventilation rate in L/hr, and the
duration ofexposure. Thevalue obtainedwould also need to be corrected
forthepercentage ofMTBE thatis notabsorbedbythelung,whichis not
known. For the rat, the following constants have been used:
(ppm x 3.61) x (8.3 L/hr x 1/1000) x hr exposure
0.25 kg body weight
The ventilation rates for the same species differ in various texts by as
much as 4-fold. The values used here have been taken from Hallenbeck
(6). Forhumans the ventilation rate value from the same reference is 833
L/hr.
achieved within 5-15 min (8,9). The peak level ofTBAwas
achieved approximately2hrafterdosing.Abouthalfofthe
MTBE dosewas eliminated through the lungs (46-54% of
oral dose and 42-46% ofintravenous dose) and one-third
through the urine (26-35%) (3). These results are similar
to those reported by Exxon (8) showing that 50-55% of
MTBE oraldosewasexhaled3hrafterexposureto40mg/
kg. The pulmonary elimination of MTBE was slightly
more rapid after intravenous dosing compared to oral
dosing, resulting in a lower peak plasma MTBE level.
After oral exposure to 400 mg/kg MTBE, the fraction of
the dose eliminated via the lungs increased to 65-69%,
similar to the pattern observed after inhalation (3). How-
ever, unlike what was observed after inhalation, the
MTBE plasma peak levels were more or less proportional
to the dose. Thus, the increase in theproportion ofMTBE
exhaled is probably due to the fact that, at higher blood
concentrations, more MTBE is partitioned into the air.
Plasma MTBE was cleared with a half-life ranging from
0.5 to 0.6 hr after inhalation and from 0.5 to 0.9 hr after
intravenous and oral administration (7,9).
The values reported above for the disposition ofMTBE
represent the total radioactivity exhaled. When the com-
position ofthe exhaled material was characterized, itwas
found that 1-4% of the exhaled material (after oral and
intravenous exposure) and 7-30% (after inhalation) was
TBA and the remainder was MTBE (Table 1). In general,
the fraction of the exhaled material that was TBA
decreased with increasing MTBE doses. Less than 1%
was C02, indicating that little MTBE is completely
oxidized (2,3). Of the total exhaled MTBE, 80-94% was
eliminated duringthefirst3 hrafterdosing, andvirtually
complete elimination had occurred 6 hr after dosing. In
parallel, the percentage of TBA in exhaled air increased
after 3 hr (2,3).
In summary, in rats MTBE is quickly absorbed and
distributed in the circulation. Depending on the dose and
route of exposure, 6-50% of the MTBE dose does not
appeartoundergometabolictransformationbutisexhaled
as such via the lung. The proportion of MTBE exhaled
increaseswiththedose. IntermsoftheMTBE peakblood
levels, exposure to 400ppmfor6 hr (total dose 285mg/kg)
alble 1. Methyl tertiary-butyl ether disposition in rats.a
% Radioactivity Tertiary-butyl alcohol,
Peak blood exhaled, % ofexhaled radioactivity
Route ofexposure Sex levels, ,ug/mL 0-48 hr 0-3 hr 0-48 hr
Inhalation
400 ppm, 6 hr M
F
M
F
8000 ppm, 6 hr
Intravenous, 40 mg/kg M
F
15
14
556
513
12
8
17
22
54
59
42
46
28
31
10
7
4
4
65
65
42
35
26
26
Oral
40 mg/kg M 17 46 4 35
F 11 54 4 27
400 mg/kg M 123 65 1 16
F 115 69 1 11
'References: Inhalation exposure: peak blood levels (7), percent exhaled (2). Intravenous and oral exposure: peak levels (9), percent exhaled (3).
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is approximately equivalent to an oral or intravenous
exposure of40 mg/kg (Table 1). However, atthese compar-
able exposures, the percentage of MTBE exhaled differs
by approximately a factor oftwo.
Acute Studies
The acute inhalation concentration ofMTBE needed to
produce death in 50% ofrats (LC50) hasbeen calculated in
different studies tobe18,000ppm(10),23,600ppm (11), and
39,500 ppm (12). The acute oral dose needed to produce
deathin50%ofrats(LD50)hasbeencalculated tobeabout
3.9 g/kg (12). Death is preceded by signs of ocular and
mucous membrane irritation, ataxia (inability to coordi-
nate voluntary movements), and central nervous system
(CNS) depression (12). In nonhuman primates, no toxic
signswere observed aftertwo exposures to 3400 and4800
ppm for 6 hr. The animals became ataxic on the third day
during exposure to 8500 ppm (13).
In humans, MTBE has been administered for the pur-
pose of gallstone dissolution through a catheter inserted
either in the bile duct or the gallbladder at doses ranging
from approximately 0.01 g/kg to 0.2 g/kg. The duration of
the infusion varied from 1-3 min to 30 min. The infused
material was usually aspirated, and the treatment
repeated several times (14-18). The investigators did not
report what fraction of the infused MTBE reached the
systemic circulation. The side effects observed were per-
spiration, transient hypotension, bradycardia, sedation,
and atransientelevation ofliverenzymes,withthedistinc-
tive smell ofether on the patient's breath. The severity of
the symptoms varied with the regimen administered and
frompatienttopatient. All symptoms usually disappeared
after the termination ofthe treatment.
In a single exposure study to evaluate acute neurotoxic
effects, ratswereexposedbyinhalationto0,800,4000, and
8000 ppm MTBE for 6 hr (19). Some of the animals were
evaluated using a battery of functional observations
(FOB) includingataxia, rectaltemperature, hindlimbgrip
strength, labored respiration, leg splay, and treadmill
duration at various times after exposure. The remaining
animals were tested for motor activity immediately after
the end ofthe exposure. In the 8000-ppm exposure group,
several FOB and motor activity changes were observed.
Occasional changes were also detected in the 4000-ppm
group, but none were seen in the 800 ppm group. The
authors interpreted these transient changes as indicative
ofCNS sedation.
In conclusion, the results ofthese studies suggest that
inhalation of MTBE vapors causes some toxicity in both
rats and nonhuman primates. Concentrations that caused
ataxia or sedation were greater than 4000 ppm for 6 hr in
both species, suggestingcomparable sensitivity to MTBE
ifpharmacokinetics are similar. Theeffects observed were
transient and disappeared after the exposure was termi-
nated. It remains to be established whether subtle behav-
ioral changes are induced at lower concentrations.
Subchronic Studies
These studies were primarily designed to evaluate
whether protracted exposures either by inhalation or
gavage in different species caused any toxicological
changes. In one study (20), ratswere exposed for 6 hr/day
for9daysto concentrations of100,300,1000,and3000ppm
MTBE. Microscopic examination ofthe nasal mucosa and
trachea revealed chronic inflammation in the two high-
dose groups. Liverweightswere significantlyincreasedin
both sexes exposed to 3000 ppm. In another study (21),
maleandfemaleratswereexposedto250,500, or1000ppm
MTBE for 6 hr/day for 13 weeks. The few treatment-
related effects were a dose-dependent anesthetic effect
and a lower weight gain in the high-concentration group.
In addition, male rats displayed a significant increase in
red blood cell hemoglobin, an increase in kidney weight,
and elevated blood-urea nitrogen (BUN) and lactate
dehydrogenase (LDH) values at 1000 ppm. A slight
decrease in absolute and relative lungweight and in blood
LDHvalueswas observedinfemales exposedto1000ppm.
The Bushy Run Research Center (22) exposed four
groups ofmale andfemaleratsfor6hr/dayfor13weeksto
MTBE vapors of0, 800, 4000, and 8000 ppm primarily to
evaluate neurotoxic effects. Body weight gains were
depressed in rats of the high-dose group for the first 3
weeks ofexposure, and corticosterone levelswereelevated
at the end of the exposure. Liver, kidneys, and adrenal
gland weights increased in a dose-dependent fashion in
both sexes in the 4000- and 8000-ppm groups. Ataxia was
seen in the 8000-ppm group during the first 4 weeks, and
minor changes were found in some functional observa-
tional tests (elevated body temperature in female rats at
4000 and 8000 ppm, decreased hind limb grip in male rats
at4000ppm). Motor activitywas decreased in male rats of
the 8000-ppm group and increased in female rats of the
4000-ppm group. No histopathological changes were
detectedinanyofthe organs exceptforanaccumulationof
hyaline drops within the proximal tubules ofthe kidney of
male rats at 8000 ppm.
Robinson et al. (23) conducted a 14- and 90-day oral
toxicity study in rats. The daily doses, administered by
gavage, were 0, 357, 714, 1071, and 1428 mg/kg for the 14
day study and 0, 100, 300, 900, and 1200 mg/kg for the 90-
day exposure. At or above doses of 1200 mg/kg, MTBE
induced temporary anesthesia and diarrhea. Total weight
gain was less for both males and females at doses above
1000 mg/kg. Relative liver weights were increased in
femaleswith doses above 1200 mg/kg, and absolute kidney
weightswereincreased inmaleswith doses above 700 mg/
kgafter eitherthe 14-day orthe90-dayexposure. Relative
kidneyweightswere alsoincreasedwith the dose afterthe
90-day exposure, and absolute lung and spleen weights
were significantly reduced in females exposed for 14 days
to the highest dose. Male rats in the two high-dose groups
displayed elevated hemoglobinvalues after14 daysbut not
after 90 days ofexposure. Bothmales and females showed
increased cholesterol levels, and females also had lower
BUN and creatinine levels. Males in the high-dose groups
from both studies displayed a higher incidence of renal
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Table 2. Methyl tertiary-butyl ether subchronic studies.
Species Exposurea Results Reference
Rats 100, 300, 1000, 3000 ppm, 6 hr/day for 9 days Increased liver weight and nasal mucosa inflammation (20)
Rats 250, 500, 1000 ppm, 6 hr/day for 13 weeks Anesthetic effects, decreased weight gain (21)
Rats 800, 4000, 8000 ppm, 6 hr/day for 13 weeks Decreased weight gain, increased liver, kidney, and (22)
adrenal weights, increased kidney hyaline droplets in
females, decreased hind limb grip and motor activity
in males
Rats 100, 300, 900, 1200 mg/kg, for 90 days Increased liver and kidney weight, increased kidney (23)
hyaline droplets in males
aNumbers in bold indicate concentrations at which effects were seen.
tube disease, which was characterized by increased
hyaline droplets in the cytoplasm of proximal tubular
epithelial cells.
In general, these studies (summarized in Table 2) sug-
gestthat MTBE is nothighlytoxic to rodents. In all cases,
MTBE caused a dose-dependent decrease in weight gain.
Other common effects that canbeidentified afterrepeated
oral doses greater than 1000 mg/kg orrepeated inhalation
of MTBE concentrations greater than 1000 ppm for 6 hr/
day are decreased lung and increased liver weight in
females and increased kidney weights in association with
higher incidence ofrenal tube disease in males. The renal
pathology observed in male rats appears to be consistent
with a sex- and species-specific damage to a2-globulin,
which can be induced also by other hydrocarbons and
whole gasoline (24). Some hematological parameters such
as erythrocyte counts and BUN appeared to also be
affected at the high doses. The concentrations of MTBE
shown to cause these effects are about three orders of
magnitude greater than those measured at service stations.
Reproductive Studies
Afewstudies havebeenconductedinrodents toevaluate
the effects ofMTBE on reproductive outcome (see Table 3
for a summary of the studies). In a single-generation
study, male and female rats were exposed to300,1300, and
3000 ppm for 6 hr/day before mating (12 weeks and 3
weeks, respectively) and then throughout mating, gesta-
tion, lactation, and a second gestation period (25). The few
effects observed were a dilated renal pelvis in adult
females and in some pups and a slight decrease in pup
viability and weight in the high dose group. Male and
female fertility indices were not affected by the treat-
ments.
In a two-generation reproductive study, rats of both
sexes wereexposed to400,3000, and8000 ppm5hr/dayfor
5 days/week for 10 weeks before breeding and for 7 days/
week during mating, gestation, and the postnatal period
(26). No effects on reproductive parameters such as fertil-
ityindices, livebirth, and pup survival were observed. The
effects reported included a reduction in body weight gain
in Fomales at 8000 ppm, a reduction in bodyweight ofFo
adultanimals ofboth sexes, and areductioninbodyweight
gain in F1 and F2 litters. In addition, liver weights were
increased in the F1 adults at 3000 and 8000 ppm, and
perinatal deaths were increased in the F2 at 8000 ppm. In
both Fo and F1 pre-breed groups, hypoactivity and lack of
startle reflex were observed at 3000 and 8000 ppm and
ataxia at 8000 ppm. The results obtained in this study are
consistent with those reported in the subehronic toxicity
studies and the fetal developmental studies described
below.
Fetal Toxicity Studies
In astudytoevaluatetheteratologicaleffects ofMTBE,
pregnantrats were exposed to250,1100, and3300 ppmfor
6 hr/day during gestational days 6-15 (27). No adverse
effects on maternal body and organ weights, uterine
implantation, and fetal size were observed. Two terato-
genicitystudies wereconductedinmice. In one study,mice
were exposed to concentrations of0,1000, 4000, and 8000
ppm for 6 hr/day from gestational days 6-15 (28). At the
twohighestconcentrations, themothersexhibited asignif-
Table 3. Methyl tertiary-butyl ether reproductive studies.
Species Exposurea Results Reference
Rat 300, 1300, 3000 ppm, 6 hr/day, premating,.gestation, Dilated renal pelves in adults/pups, decreased pup (25)
lactation, second gestation survival and weight in second generation pups, no
effect on fertility indices
Rat 400, 3000, 8000 ppm, 5 hr/day; Fo premating, Decreased weight gain in Fo rats and F1 litters, (26)
gestation, pup growth (=F1); F1 premating, gestation, increased liver weights in F1 adults, decreased
pup growth (=F2) perinatal deaths in F2 litters, ataxia and hypoactivity
in Fo and F1 adults, no effects on reproductive indices
aNumbers in bold indicate concentrations at which effects were seen.
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icantreductioninbodyweightandclinicalsignsoftoxicity,
including hypoactivity, ataxia, lacrimation, and labored
respiration. At these concentrations, the number ofviable
implants per litter was reduced. Fetal bodyweights were
significantly reduced at 4000 and 8000 ppm. An increased
incidence ofcleft palate was observed at 8000 ppm and of
skeletal malformations at both 4000 and 8000 ppm. In a
similar study performed by a different group (29), preg-
nantmice wereexposed to0,250, 1000, and2500 ppm6hr/
dayduring gestational days 6-15. No adverse effects were
observed in the dams. A slight increase in the number of
fetal resorptions and in the incidence offused sternebrae
in the offspring were detected, but these effects were not
considered to be treatment related.
In pregnant rabbits exposed to concentrations of 0,
1000,4000, and8000 ppmMTBE 6hr/dayfromgestational
days 6-18, a significant reduction ofweight gain and food
consumption was observed at the two highest exposures,
and anincreaseinrelativematernalliverweightwas noted
at 8000 ppm (30). Gestational parameters, including num-
ber of corpora lutea, number of implantation, fetal body
weight, and number of fetal malformations, exhibited no
significant changes.
In conclusion, maternal toxicity was observed in both
rats and rabbits at 4000 and 8000 ppm and in mice at
8000 ppm (Table 4). Increased frequency offetal malfor-
mation and decreased number of viable implantations
were found onlyinmice at4000 and8000 ppm, indicating
the mouse fetus may be more sensitive to MTBE than
the rat fetus.
Conclusions
In summary, the studies presented indicate a low tox-
icity ofMTBE in rodents. However, limited information is
available regardinghealth effects in humans ornonhuman
primates. Because of the considerable differences in spe-
cies susceptibility to methanol (see below) and the lack of
data in primates, one cannot rule out the possibility that
MTBE may be toxic to humans at high doses. In fact,
formate is a metabolite of MTBE and may accumulate
above a certain dose of MTBE. The contribution of the
pathway leading from MTBE to formate is unknown.
Based on the rodent data and the current exposures
associated with refueling at less than 1 ppm, there seems
little likelihood of a severe hazard to healthy individuals
under normal use conditions. However, there may be sub-
populationsthat are moresusceptibletoMTBE.Moreover,
withincreasedmarketpenetration, MTBE exposurelevels
and the number of people exposed will increase. Phar-
macokinetic data on the disposition and metabolism of
MTBE in primates and exposure information for other
scenarios such as garages, street canyons, and inside the
car are necessary to better assess the risk of MTBE
exposure to humans. In addition, because of its lipid
solubility, MTBE may be a neurotoxicant; neurotoxicity
studies would be prudent.
Methanol
Methanol has been used since the beginning of the
centuryas asolvent,and, morerecently, as afuelforracing
cars. In the last few years efforts have been made by
government officials, state regulators, and others to pro-
mote the use ofmethanol as areplacement to gasoline and
diesel fuels for passenger cars, buses, and other fleet
vehicles in ordertoimprove airquality. Itispredictedthat
use ofmethanol-fueled vehicles would decrease the levels
of some pollutants; however, this practice would increase
exposure ofthe general public to methanol and, in certain
microenvironments, to formaldehyde, a product of meth-
anol combustion.
Some methanol exposure concentrations have been cal-
culated for various scenarios from emission data from a
few cars running on methanol using dispersion models
that take into account, for the various scenarios, traffic
conditions, meteorological conditions, and wind patterns
(31). The highest concentration, projected to occur in a
personal garage, is 375 ppm during the cold start. In
public garages, assuming100% ofthevehicles were fueled
with methanol, concentrations are projected to be as high
as 150 ppm. In other scenarios, the concentrations are
expected to be lower than 50 ppm. In the majority ofthe
cases, exposure of the general public would be brief but
repeated in time.
Metabolism and Pharmacokinetics
Regardless ofthe species and route of exposure, meth-
anol is rapidly absorbed and distributed to the tissues in
proportion to water content (32). Unlike MTBE, most
methanol (more than 90%) is metabolized in the liver and
Table 4. Methyl tertiary-butyl ether fetal toxicity studies.
Species Exposurea Results Reference
Rat 250, 1000, 3300 ppm, 6 hr/day, gestation days 6-15 No effects in dams/offspring (27)
Mouse 1000, 4000, 8000 ppm, 6 hr/day, gestation days 6-16 Decreased weight gain in dams/fetuses, increased (28)
fetal resorption and incidence of skeletal
malformations
Mouse 250, 1000, 2500 ppm, 6 hr/day, gestation days 6-15 No effects in dams, increased fused sternebrae in (29)
offspring
Rabbit 1000, 4000, 8000 ppm, 6 hr/day, gestation days 6-18 Decreased weight gain in dams, increased liver weight (30)
in dams, no fetal toxicity or malformations
aNumbers in bold indicate concentrations at which effects were seen.
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exhaled as CO2, and only a small fraction is excreted
directly through the lung (2.5%) or in the urine (1%) at
methanol doses smaller than 1 g/kg. At 1 g/kg, about 78%
of the dose is still recovered as exhaled CO2 (32). In the
case of inhalation, on the order of 60-85% of inhaled
methanol is absorbed by the lung (33,34).
Inallmammalian speciesstudied,thesequenceofmeta-
bolicintermediates leadingfrommethanol to its endprod-
ucts in the liver is the same. The first stepis the oxidation
ofmethanol to formaldehyde, mediated primarily by alco-
hol dehydrogenase in nonhuman primates and humans
and by a catalase-peroxidase system in rats (35). Despite
these differences, Tephly and McMartin (35) determined
that the rate of formaldehyde production was approx-
imately the same in the different species. The disap-
pearance ofmethanolintheblood ofrats appears tofollow
first-order kinetics with a half-life of 2-3 hr at body
burdens as high as 80 mg/kg and zero-order kinetics at
higher doses (32). A similar half-life was determined in
nonhuman primates exposed up to 2000 ppm for 6 hr (36).
Formaldehyde is quickly metabolized to formate in all
species studied (37). FormateisthenconvertedtoCO2 and
waterby a pathway dependent on tetrahydrofolate, which
is derived from folic acid in the diet and is the major
determinant of the rate of formate disposition (38,39). A
small proportion offormate is also excreted in the urine.
The folate-mediated metabolism of formate has been
shown to proceed about 2-2.5 times faster in rats than in
nonhuman primates and humans (35) and to lead to toxic
accumulation of formate in blood in the latter species at
sufficiently high doses ofmethanol (greater than 200 mg/
kg) (32). The accumulation offormate normally reaches a
plateau between 12 and 24 hr after exposure to methanol.
Detailed pharmacokinetic data on methanol disposition
aftervarioustypesofexposureandindifferentspeciesare
beinggathered but are notyet available. In general, blood
methanol levels peaked at the end ofthe exposure period
(40). In rats, methanol blood levels did not increase in
proportion to the vapor concentration. With a 6-hr expo-
sure, there was a greater increase between 1200 and 2000
ppm for 6 hr than between 200 and 1200 ppm (41). In
nonhuman primates, however, theblood levels appeared to
be directly proportional to the exposure up to 2000 ppm
(36).Thebloodlevelswerecomparableinratsandmonkeys
uptoexposuresof1200ppm.Bloodformatelevelswerenot
increased in either species, indicating that these two spe-
cies do not substantially differ in the metabolism ofmeth-
anol at low levels of exposure.
Acute Studies
Methanol has been recognized as a human toxic agent
sincetheendofthenineteenthcentury. Ingestionhasbeen
the predominant route of poisoning, but percutaneous
absorption of methanol liquids has also been shown to
produce toxic effects.
A review of reports of methanol poisoning present a
characteristic sequence of symptoms including metabolic
acidosis, loss of motor coordination, and blindness. These
symptoms, which occur after an asymptomatic period of
12-24 hr, can lead to coma and death or permanent blind-
ness (42) and have been attributed to the accumulation of
toxic levels of formate (43). Although the visual system,
andparticularlytheopticnerve,appearstobetheprimary
targetofmethanoldamage, autopsiesindicatethatcertain
brain areas, such as thebasal ganglia, also presentpatho-
logical abnormalities (32). Among the various species
tested, only nonhuman primates display the acute effects
observed in humans (44). As discussed earlier, the dif-
ferences in species susceptibility have been attributed to
the different rates ofdisposition offormate. In fact, toxic
symptoms can be induced by methanol in rats by altering
their folate status and, as a consequence, formate
accumulation (38,45). Therefore, it is possible that people
with dietary folate deficiency may also exhibit greater
susceptibility to methanol toxicity, though there is no
experimental evidence as yet to support this view. This
potentialisofconcernbecausefolatedeficiencyisobserved
in some pregnant women and may be associated with an
increased rate of neural tube defects (46,47).
The LD50forrats hasbeen determinedtovarybetween
7and13mL/kg(48); theminimallethaldoseofmethanolin
humans ranges between 300 and 1000 mg/kgbodyweight
(or 0.375-1.25 mL/kg) (32). The estimated methanol dose
toincreaseformatelevelsinhumansis200mg/kg(32).The
exposure in the worst-case scenario for methanol-fueled
cars (personal garage) would produce a methanol body
burden ofless than 1 mg/kg (32) . Based on blood formate
levelsresultingfromlaboratoryand occupationalexposure
studies,itisconsideredunlikelythatmeasurableincreases
in blood formate would occur in human adults even under
the worst-case exposure scenario for a personal garage.
Thus, acute toxic effects would not be expected from the
normaluse ofmethanolfuel. However, methanolpoisoning
as aresult ofaccidents or abuse mayrepresent apotential
health threat ifmethanol fuel were introduced on a large
scale.
A few studies have been conducted to evaluate the
effects on behavior ofacute, nontoxic methanol exposures.
Inonepilotstudy,12healthyhumansubjectswereexposed
to 192 ppm methanol vapor for 75 min (49). Neu-
robehavioral tests and neurophysiological measurements
were made before, during, and immediately after expo-
sure. Most behavioral end points showed no association
withmethanol exposure. Smallbut statisticallysignificant
effects and trends were found only for the subjective
rating offatigue, measurement ofinterference by a stim-
ulus on the subject's ability to focus attention, and the
latencyoftheearlycomponents ofthe electrophysiological
response evoked by an acoustic and visual stimulus. The
functional significance of this component is a matter of
controversy. However, none of these effects exceeded the
normal range of values. Other tasks measuring reaction
time, information processing, and vigilance were not
affectedbytheexposure. Becausethispilotstudyincluded
only one concentration ofmethanol and a limited number
ofsubjects, it is difficult to determine whether the results
obtained are indicative of subtle effects on some human
neurobehavioral functions. Additional studies are needed
to confirm or disprove this study.
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In a study by Mullenix et al. (50), adult rats were orally
administered the artificial sweetener aspartame (which
decomposes in the gut to 40% aspartate, 50% phe-
nylalanine, and 10% methanol) atadose of500 or1000 mg/
kg (corresponding to a methanol dose of 50 and 100 mg/
kg). One hour after dosing, the animals' spontaneous
behavior was recorded by a computer pattern recognition
system. No significant changes were observed.
In summary, the information available indicates that
methanol is more toxic to humans than rodents, but it is
inconclusive about whether less severe acute effects could
occuratdosesthatdo notcause overttoxicity, particularly
in sensitive subpopulations.
Repeated Exposure Studies
The literature on the effects of repeated exposure to
methanol concentrations similar to those thatwouldresult
from the introduction ofmethanol fuels isvery limited. As
a point of reference, the American Congress of Govern-
mental Industrial Hygienists setthe threshold limitvalue
(TLV) for occupational exposure at 200 ppm time-
weighted average foran8-hrperiod (51). Such anexposure
would result in a methanol body burden ofapproximately
25 mg/kg (calculated as the product of methanol con-
centration in mg/m3, duration ofexposure, andventilation
rate divided bybodyweight. Formethanol, the conversion
factor from ppm to mg/M3 is 1.3).
There is some evidence from epidemiological studies of
workers exposed to methanol from duplicating machines
that repeated sublethal doses (less than 0.3 g/kg body
weight and above the TLV of 200 ppm) may cause head-
ache, dizziness, nausea, and blurred vision, indicating that
methanol exposure can result in CNS depression (52,53).
The exposure duration in the latter studywas reported to
range from 1 hr/dayfor 1 day/week to 8 hr/day for 5 days/
week and had presumably been occurring for about 3
years. The conclusions, however, are based onreporting of
symptoms. The effects in these studies are similar in
nature to those from acute intoxication, but appear less
severe.
In Japan, the New Energy Development Organization
(NEDO) (54) sponsored a study to evaluate the effects of
protracted exposure to methanolvapor (10, 100, 1000 ppm,
21hr/dayfor7-25months) innonhumanprimates. In afew
animals some degeneration of astrocytes or increase in
their number in some areas ofthe brain was observed at
the 100 and 1000 ppm exposures, even after the shorter
exposure duration. The authors considered these changes
to bereversible and did notbelieve them to be ofbiological
significance. Monkeys exposed to 1000 ppm for more than
2 years also showed degeneration ofthe inside nucleus of
the thalamus, cerebralwhite cortex, liver, and kidney. In a
fewanimals, from each exposure group, a slightdegenera-
tion of the optic nerve was suspected, but the authors
concluded that overall no significant degeneration of the
optic nervewasobserved. However, inmonkeysexposedto
3000 ppm or 5000 ppm, but not to 2000 ppm, for 21 hr/day
for 20 days and then allowed to recover for 10 months, a
slight atrophy of the optic nerve and a reduction in mye-
linated opticnerve cellswas observed. Theresults ofthese
studies are interestingbut are presentedwith insufficient
detail to permit critical evaluation and have not been
published as yet in the peer-reviewed literature.
NEDO also conducted a 24-month carcinogenicity
studyin rats exposed to methanolvapors of0, 10, 100, and
1000 ppm for 19 hr/day and a 18-month carcinogenicity
study in mice exposed to 0, 10, 100, 1000 ppm for 19 hr/day
(54). The exposures did notaffect bodyweight or survival
ratesineitherspecies. Pathologicalexaminationrevealeda
slightly higher incidence of tumors in the lung (papillary
adenoma)inmaleratsinthe10and1000ppmgroupsandof
tumors of the adrenal gland (chromaffinoma) in female
rats in the 1000 ppm group. No significant histopathologi-
cal changes were observed in mice. These results suggest
that methanol is not carcinogenic in mice and raise the
possibilitythatmethanolmaybe aweak carcinogen in rats.
In summary, these studies provide weak evidence that
protracted exposure to methanol vapors may damage the
central nervous and visual systems, but additional work
would be helpful to define clear dose-response relation-
ships.
Developmental Toxicity Studies
A few studies in rodents have indicated that fetal meth-
anol exposure at high doses can be teratogenic and have
developmental effects. InonestudyconductedbyNelsonet
al. (55), the teratogenic effects ofmethanolwere evaluated
in pregnant rats exposed to concentrations of methanol
ranging from 5,000 to 20,000 ppm (25-100 times the TLV)
orofethanol from10,000to 20,000ppmfor 7hr/dayforthe
entire duration of gestation. Although methanol was not
toxic to the dams, ethanol caused complete narcosis at
20,000 ppm and hyperactivity at the lower dose. The
highest concentration ofmethanol (20,000 ppm) produced
a high incidence ofcongenital malformations and urinary
tract and cardiovascular defects. No definite increase in
malformations was observed at any ethanol dose.
Other studies compared theteratogenic effects ofmeth-
anolin rats (56) andmice (57). Pregnantratswereexposed
to 15,000 ppm 7 hr/day on gestational days 7-19, and
pregnant mice were exposed to 0, 2000, 5000, and 15,000
ppm methanol vapors 7 hr/day on gestational days 6-15.
The rat study confirmed the results ofNelson et al. (55) in
that exposure to 15,000 ppm was not teratogenic. Mice,
however, appeared to be more sensitive. All the exposed
mouse dams gained less weight than the controls. Most of
the litters ofdams exposed to 15,000 ppm were completely
resorbed, and 38% ofthe fetuses surviving to day 17 had
exencephaly. Exposure to 5000 ppm resulted in
exencephaly in about one-third ofthe litters and 5-10% of
all fetuses. No effects were observed at the 2000-ppm
exposure.
In the studyby Infurna and Weiss (58), early postnatal
behaviorwas evaluated in rats aftermaternal ingestion of
an average daily dose of methanol of 2.5 g/kg during
gestational days 15-17 or 17-19. The results indicated that
both groups of methanol-exposed pups required longer
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than controls to begin suckling (at postnatal day 1) and
more time to locate nestingmaterial fromtheirhome cage
(at postnatal day 10). No signs of overt toxicity were
apparent in either the mothers or the offspring. A similar
study was conducted by Stanton et al. (56) in rats exposed
to 15,000 ppm for 7 hr/day on gestational days 7-19. A
number oftests were performed during pup development
(from postnatal day13 to day 73), including tests ofmotor
activity, learning, andreaction time, but none was affected
by the prenatal methanol exposure.
A study conducted by NEDO (54) in rats exposed to
methanolfor an averageof20hr/dayat200,1000, and5000
ppm during gestation and lactation showed a decreased
brain weight in the high-dose group, but no brain histo-
pathological changes. Exposure of pregnant rats to 5000
ppm methanol, but not to 1000 ppm, during gestation days
7-17 caused lower survival and birth rate, visceral and
skeletal malformation, and decreased weight of the thy-
roid and the brain.
In summary, methanol appears tobe teratogenicin rats
at exposure levels greater than 15,000 ppmfor6 hr or5000
ppm for 20 hr, and in mice at levels of 5,000 ppm for 6 hr
(Table 5). However, these mouse studies are ongoing, and a
definite no-adverse-effect level (NOAEL) has not been
established. Early postnatal behavior of rats may be
affected by in utero exposure to 2.5 g/kg, but behavioral
testsperformed in developingrat pupsexposed inutero to
15,000 ppm 7 hr/day were not affected.
Conclusions
Ingestion of or dermal exposure to high doses ofmeth-
anol can cause toxic andlife-threatening effects inhumans
but not in rodents. However, these effects have been
attributed to the accumulation of the metabolite formate
and should not occurinnormalindividuals atthepredicted
exposure levels from normal use ofmethanol as afuel. The
analysis of the data currently available regarding effects
of low-level exposures points out many uncertainties and
assumptions that need to be verified to estimate human
risk for realistic exposure levels. For example, there is
limited information about the dose-response relationship
on neurotoxic and visual end points and on fetal develop-
ment across species at both single and repeated low-level
exposure. These end points may be sensitive to methanol
exposure. There are also no data about the potential
susceptibility to methanol of individuals with dietary
folate deficiency. The exposure information thatwould aid
in the design of new studies is limited and is derived from
testing a small number of cars whose engines were not
optimized to run onmethanol. Thisinformationwould also
enable extrapolation ofthe available data to human expo-
sure levels.
Discussion
In general, MTBE appears to have relatively low tox-
icity in rodents. No specific target organs have been
identified except for the male rat kidney and possibly the
female ratlungand liver. The effects observed, changes in
organweightandrenalhyalinedropletaccumulation, were
induced by MTBE concentrations much greater and of
much longer duration than those to which humans would
beexposedfrom use ofMTBE ingasoline. Thereislimited
information about health effects in other species. One
study of nonhuman primates was exclusively aimed at
evaluating gross psychomotor effects at high concentra-
tions. The onlyhuman studies are clinical studies inwhich
MTBE was infused to the gall bladderfor gallstone treat-
ment. These studies indicate that, with the exception of
sedation, MTBE did not cause any overt toxicity. Taken
together, the results of all these studies suggest that
exposure to MTBE derived fromits use as a component of
gasoline is unlikely to pose a health risk to the general
public. This conclusion is limited by the fact that phar-
macokinetic data in nonhuman primates and humans,
which would be useful for extrapolation of the rodent
findings to humans, are not available, and some possible
relevant end points have not been studied.
Methanol is known tobe toxicinhumans and nonhuman
primates, but it is considerably less toxic in rodents. The
acute toxicity studies raise concern aboutthe introduction
Table 5. Methanol fetal toxicity studies.
Species Exposurea Results Reference
Rat (teratology) 5000, 10,000, 20,000 ppm, 7 hr/day, gestation Congenital malformations, urinary tract, and (55)
days 7-15 cardiovascular defects
Rat (teratology) 15,000 ppm, 7 hr/day, gestation days 7-19 No teratogenic effects (56)
Rat (teratology) 200, 1000, 5000 ppm, 22 hr/day, gestation days Decreased weight gain in dams, increased fetal (54)
7-17 resorptions, decreased pup survival, visceral and
skeletal malformations
Mouse (teratology) 2000, 5000, 15,000 ppm, 7 hr/day, gestation days Decreased weight gain in dams. Increased (57)
6-15 execenphaly, increased fetal resorptions
Rat (fetal 2.5 g/kg/day, gestation days 15-17 or 17-19 Delayed suckling and nesting behaviors (58)
development)
Rat (fetal 15,000 ppm, 7 hr/day, gestation days 7-19 No effect on motor activity, learning, or reaction (56)
development) time
aNumbers in bold indicate concentrations at which effects were seen.
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of methanol as a fuel for two reasons. First, there are
safety issues that need to be taken into consideration to
preventaccidents andabuse andreduce occupationalexpo-
sure. Second, there is concern that even the low levels of
exposure projected from use of methanol as a fuel, if
protracted, may cause subtle effects, particularly to the
visual and nervous system. In 1987 a special report issued
bythe Health Effects Institute (HEI) (59) concluded that
exposure to methanol vapor from the use ofmethanol as a
motorvehicle fuelwas notlikelytoresultinadverse health
effects. However, the reportalsoidentified research needs
to reduce the level of uncertainty about this conclusion.
Numerous studies are currently funded, not onlyby HEI,
but also by other agencies, to address some issues of
concern. Similarly, work is being done on MTBE that will
clarifypossible oncogenic effects. One active areaofmeth-
anol research is that ofdevelopmental effects ofmethanol
invarious species. Theresults sofaravailable indicate that
the mouse fetus is more sensitive to maternal methanol
exposure than the rat fetus. This was also observed with
MTBE exposure. Additional studies would be helpful to
determine which species is the best model for humans.
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tion Agency and Jane Warren of the Health Effects Institute for their
helpful comments during the preparation ofthe manuscript. The Health
Effects Institute (HEI) is an organization jointly funded by the U.S.
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